Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo

Nicola M. G. Smith,1,a Petra Mlcochova,2,a Sarah A. Watters,2,a Marlene M. I. Aasa-Chapman,2 Neil Rabin,3 Sally Moore,3 Simon G. Edwards,4 Jeremy A. Garson,2 Paul R. Grant,2 R. Bridget Ferns,2 Angela Kashuba,2 Neema P. Mayor,6,7 Jennifer Schellekens,6,7 Steven G. E. Marsh,6,7 Andrew J. McMichael,1 Alan S. Perelson,8 Deenan Pillay,2,9,b Nilu Goonetilleke,1,10,b and Ravindra K. Gupta2,b

1Nuffield Department of Medicine, University of Oxford, 2Department of Infection, Division of Infection and Immunity, University College London, 3University College London Hospitals National Health Service (NHS) Foundation Trust, and 4Mortimer Market Centre, Central and North West London NHS Foundation Trust, United Kingdom; 5Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill; 6Anthony Nolan Research Institute, Royal Free Hospital, and 7Cancer Institute, University College London, United Kingdom; 8Los Alamos National Laboratory, New Mexico; 9Africa Centre for Health and Population Sciences, University of KwaZulu Natal, South Africa; and 10Department of Microbiology & Immunology, University of North Carolina at Chapel Hill

Background. Emerging data relating to human immunodeficiency virus type 1 (HIV-1) cure suggest that vaccination to stimulate the host immune response, particularly cytotoxic cells, may be critical to clearing of reactivated HIV-1–infected cells. However, evidence for this approach in humans is lacking, and parameters required for a vaccine are unknown because opportunities to study HIV-1 reactivation are rare.

Methods. We present observations from a HIV-1 elite controller, not treated with combination antiretroviral therapy, who experienced viral reactivation following treatment for myeloma with melphalan and autologous stem cell transplantation. Mathematical modeling was performed using a standard viral dynamic model. Enzyme-linked immunospot, intracellular cytokine staining, and tetramer staining were performed on peripheral blood mononuclear cells; in vitro CD8 T-cell–mediated control of virion production by autologous CD4 T cells was quantified; and neutralizing antibody titers were measured.

Results. Viral rebound was measured at 28 000 copies/mL on day 13 post-transplant before rapid decay to <50 copies/mL in 2 distinct phases with t1/2 of 0.71 days and 4.1 days. These kinetics were consistent with an expansion of cytotoxic effector cells and killing of productively infected CD4 T cells. Following transplantation, innate immune cells, including natural killer cells, recovered with virus rebound. However, most striking was the expansion of highly functional HIV-1–specific cytotoxic CD8 T cells, at numbers consistent with those applied in modeling, as virus control was regained.

Conclusions. These observations provide evidence that the human immune response is capable of controlling coordinated global HIV-1 reactivation, remarkably with potency equivalent to combination antiretroviral therapy. These data will inform design of vaccines for use in HIV-1 curative interventions.

Keywords. elite control; HIV; cure; CD8; myeloablation.

Received 18 January 2015; accepted 9 February 2015.

© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI: 10.1093/cid/civ219

To date, the “Berlin patient” is the only known human immunodeficiency virus type 1 (HIV-1)–infected individual to achieve sustained nondetectable viremia without rebound following removal of combination antiretroviral therapy (cART). This success is likely due to a combination of transplantation with cells from a donor who lacked the chemokine (C-C motif) receptor 5 HIV-1 coreceptor that limited HIV-1 propagation, total body irradiation that depleted existing latent infected cells, and graft vs host disease. These observations have sparked the search for novel approaches to clear
HIV reservoirs that reside largely in resting memory CD4+ T cells.

Recently, Shan et al, using an in vitro model of HIV latency, observed that HIV-1 reactivation was not itself adequate to destroy infected cells but that coculture with antigen-stimulated CD8+ T cells could clear reactivated cells. This suggests that in addition to strategies that reactivate HIV latent infected CD4 T cells, future cure approaches may also need to stimulate immune responses, for example, through vaccination [1].

The host immune response plays a clear role in maintenance of virus load (VL) control in HIV-1 infection. The clearest example of this can be found in HIV-1–infected individuals who maintain VL <50 copies/mL without receiving cART (approximately 0.3% of HIV-1–infected individuals). These individuals, termed elite controllers (ECs), control acute HIV-1 viremia within weeks to months of infection [2], have higher CD4 T-cell counts than non-ECs, and progress far more slowly to AIDS [3]. CD8 T cells have been implicated in HIV-1 control in ECs largely because of enrichment of certain major histocompatibility complex class I alleles (human leucocyte antigen [HLA]-B*57, HLA-B*27, HLA-B*81) that are also associated with lower VLs and slower disease progression [4–8]. Protection in these individuals is thought to be largely mediated by the induction of HIV-1–specific CD8 T cells restricted predominantly by these HLA alleles. Mapping of these “protective” CD8 T-cell responses in ECs demonstrates that they typically target more conserved regions of HIV-1, commonly within the Gag protein. During chronic infection, HIV-1–reactive CD8 T-cell responses restricted by protective HLA are normally very strong or immunodominant within the individual. HIV mutation and escape from CD8 T-cell responses, when detected, have been associated with subsequent disease progression [9–11]. Further evidence of the role of CD8+ T cells comes from studies of macaques in which removal of anti-simian immunodeficiency virus (SIV) CD8+ T cells during acute infection and chronic infection resulted in loss of virus control, with control regained as CD8+ T cells returned [12–15].

Recent reports have highlighted the fact that elite virus control does not equate to HIV cure. ECs exhibit ongoing inflammation and innate immune activation, and have lower CD4 counts relative to uninfected individuals [16]. These symptoms are, in part, driven by residual levels of virus, with recent studies showing that cART can reduce inflammation in ECs [17]. This leaves the question of how well the immune response in chronically infected individuals, even in ECs, could respond to a coordinated global reactivation of the HIV reservoir proposed in HIV cure strategies.

In this study, we report a HIV-1–infected, antiretroviral therapy (ART)-naïve EC who was treated for refractory myeloma with melphalan-induced myeloblation and an autologous stem cell transplant (ASCT). Shortly after treatment, HIV-1 reactivation to 28 000 copies/mL was observed followed by rapid control of viremia to <50 copies/mL, remarkably at rates comparable to ART. This patient represents the first example of post-transplantation constraint of a large-scale virus reactivation mediated by the human immune response, presenting an unprecedented opportunity to measure both kinetics and in vitro correlates of efficacy.

METHODS

Total DNA Polymerase Chain Reaction

The duplexed polymerase chain reaction (PCR) was performed using 600 ng of patient template DNA with forward and reverse primer pairs for pyruvate dehydrogenase (PDH), PDH probe, long terminal repeat (LTR), and LTR probe. PCR was performed using Qiagen Multiplex Mastermix at 95°C for 15 minutes followed by 50 cycles at 94°C for 1 minute and 60°C for 1 minute. Assays were carried out in triplicate, and results were expressed as total HIV DNA copies per million cells.

CD8 T-Cell Antiviral Assay (Extracellular p24)

The assay was performed as previously described [18].

ELISpot for Interferon-γ Secreting Peripheral Blood Mononuclear Cell

T-cell epitopes were initially mapped against proteome-wide consensus clade C peptides (overlapping 15–18mers) in interferon-gamma (IFN-γ) ELISpot using peripheral blood mononuclear cells (PBMCs) collected at day 336. Peptides were then tested in triplicate at days 41 and 42 as previously described [19], and optimal epitopes were defined. Positive T-cell responses were 4× background and >30 spot forming units/10⁶ cells following background subtraction [20].

Intracellular Cytokine and Tetramer Staining

See Supplementary materials for details.

Flow Cytometry of Lymphocyte Cells

See Supplementary materials for details.

Mathematical Modeling

A standard viral dynamic model [21] of HIV infection and effector cell responses was analyzed and represented as a system of differential equations (see Supplementary materials) that were then solved numerically using Berkeley Madonna v8.3.18.

RESULTS

A 59-year-old HIV-1 EC was treated for refractory myeloma using melphalan-induced myeloblation followed by an ASCT totaling 1.9 × 10¹⁰ cells. The ASCT contained both CD34 stem cells and mature lymphoid cells. The patient received etoposide–methylprednisolone–cytarabine–cisplatin conditioning and granulocyte colony-stimulating factor (CSF) to mobilize stem cells to the periphery. ART was not given in view of
undetectable VL and concerns regarding drug toxicity. The melphalan treatment precipitated neutropenia and lymphopenia at +6 days (Supplementary Figure 1), at which time the HIV-1 VL had rebounded to 17,000 copies/mL (Figure 1A). At +13 days the lymphocyte count had increased to 1280 cells/mm$^3$ and VL was 28,000 copies/mL (Figure 1A). The post-transplant environment contains high levels of interleukin-7 (IL-7) and IL-15, known to support homeostatic proliferation of memory, largely effector T cells, and may promote reactivation of HIV-1 from latently infected cells [22]. Consistently, CD4 T cells in this patient in the weeks following reactivation (day +21, day +42) exhibited a largely effector phenotype (Figure 1B). Cells showed elevated activation, as measured by CD38 and programmed death 1 (PD1) staining and increased Ki67 staining (Figure 1C, Table 1), without change in cell surface CD4 levels (data not shown), providing conditions conducive to HIV-1 reactivation and propagation.

The VL rebound doubling time was 0.5 days, similar to that observed in acute infection (0.65 days) [23]. Importantly, the observation confirms that this EC harbored a fully replication-competent virus. This was followed by a VL decay characterized by 2 phases (Figure 1A), the first with $t_{1/2}$ of 0.7 days and the second with $t_{1/2}$ of 4.1 days. This first rate was derived from 2 measurements and therefore is subject to greater measurement error. We therefore incorporated the intraassay variability of the clinical VL test (1.9 fold), as determined by replicate measurements against known standards in our calculations. This produced an estimate of first phase $t_{1/2}$ of 0.49–1.27 days. Comparison of these calculated rates with those described following ART treatment showed that the average first phase $t_{1/2}$ of

### Figure 1

**Dynamic changes in human immunodeficiency virus (HIV) viremia and CD4 T-cell activation levels following transplantation of CD34-enriched peripheral blood stem cells (day 0).**

**A**, Plasma HIV-1 RNA (copies/mL; blue circles), total lymphocyte count ($\times 10^3$ /mm$^3$; red squares), and total viral DNA (HIV-1 copies/million peripheral blood mononuclear cells [PBMCs]; black triangles) over time following reinfusion of stem cells demonstrating first and second phase decay (dotted lines). Dashed line represents the lower limit of detection of the HIV-1 RNA viral load assay (50 copies/mL plasma). Note: The first HIV DNA measurement was below the limit of detection and has been plotted at 10 copies due to limitations of a logarithmic scale. Cytotoxic chemotherapy was administered at day 1. **B**, Frequency of CD4 naive and memory subsets over time: Tcm = central (CD45RO$^+$CD27$^+$) memory, Tem = effector (CD45RO$^+$CD27$^-$) memory (C). The frequency of CD38 (red) and PD1 (blue) on CD4 T lymphocytes following stem cell infusion relative to plasma virus loads (black spheres). Inserts in (B) and (C) show cell subset frequencies in the pretreatment leukapheresis sample (autologous stem cell transplant [ASCT]).
Table 1. Changes in Lymphocyte Populations From Autologous Stem Cell Transplant to Resolution of Viremia

<table>
<thead>
<tr>
<th>Days Post-Transplant</th>
<th>&lt;41</th>
<th>21</th>
<th>42</th>
<th>472</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Viral load</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percentage of live lymphocytes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NK cells (CD56+)</td>
<td>0.18</td>
<td>1.51</td>
<td>1.58</td>
<td>2.29</td>
</tr>
<tr>
<td>Of which CD16+CD56bright</td>
<td>ND</td>
<td>0.68</td>
<td>2.69</td>
<td>2.20</td>
</tr>
<tr>
<td>Of which CD16+CD56dim</td>
<td>ND</td>
<td>77.7</td>
<td>84.8</td>
<td>81.4</td>
</tr>
<tr>
<td>Of which CD16−CD56dim</td>
<td>ND</td>
<td>1.02</td>
<td>2.28</td>
<td>4.00</td>
</tr>
<tr>
<td>Of which CD16−CD56dim</td>
<td>ND</td>
<td>22.6</td>
<td>11.2</td>
<td>0.00</td>
</tr>
<tr>
<td>NKT-like cells (CD3+CD56+)</td>
<td>2.30</td>
<td>3.27</td>
<td>2.01</td>
<td>1.59</td>
</tr>
<tr>
<td>CD3 T cells (CD3+CD8−)</td>
<td>92.8</td>
<td>86.4</td>
<td>96.0</td>
<td>88.6</td>
</tr>
<tr>
<td>CD8 T cells (CD3+CD8+)</td>
<td>23.4</td>
<td>69.1</td>
<td>74.1</td>
<td>46.5</td>
</tr>
<tr>
<td>B cells (CD3−CD19+)</td>
<td>0.00</td>
<td>0.06</td>
<td>0.12</td>
<td>2.25</td>
</tr>
<tr>
<td><strong>Proliferation: % Ki67+</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NK cells</td>
<td>92.5</td>
<td>92.1</td>
<td>81.5</td>
<td>10.5</td>
</tr>
<tr>
<td>NKT cells</td>
<td>58.3</td>
<td>63.0</td>
<td>75.3</td>
<td>3.20</td>
</tr>
<tr>
<td>CD8+ T cells</td>
<td>100</td>
<td>99.7</td>
<td>99.8</td>
<td>1.62</td>
</tr>
<tr>
<td>CD4+ T cells (CD3+CD8−)</td>
<td>90.9</td>
<td>90.5</td>
<td>99.0</td>
<td>1.77</td>
</tr>
<tr>
<td>B cells</td>
<td>50.0</td>
<td>39.5</td>
<td>39.5</td>
<td>4.24</td>
</tr>
</tbody>
</table>

Lympocyte populations were assessed by flow cytometry and are shown as a percentage of the total live cells (as determined by an anti-reactive viability dye) present in each sample. Autologous stem cells for day −41 or peripheral blood mononuclear cell for days 21, 42, and 472.

Abbreviations: ND, not determined due to too few cells in the parent gate for analysis; NK, natural killer.

* Defining markers for each population are shown in brackets.

0.7 days was very similar to a published estimate for the most potent cART [24]. The second phase $t_{1/2}$ of 4.1 days was significantly shorter than previous published estimates of 14.25 (99% confidence interval, 4.78–23.70), derived using less potent antiretroviral combinations [25]. The measured peak in plasma VL RNA was accompanied by a rise in total HIV-1 DNA levels in PBMC from <10 copies/10⁶ cells pre-melphalan treatment to 127 copies/10⁶ cells at day +13, before subsequent decay with a $t_{1/2}$ of 3.8 days (black triangles, Figure 1A).

By day +37, the VL had declined to undetectable levels. During the observed VL decline (day +13 to day +37), CD4 T-cell counts were >300 cells/mm³ (Figure 1A) compared with a total lymphocyte count of 70 cells/mm³ at day +6. Therefore, limited target cell availability is unlikely to have accounted for the VL decline. These cell kinetics were consistent with review of the terminal half-lives of the patient’s pre-transplant conditioning regimens that suggested that the drugs received were unlikely to have impacted immune cell viability and function in the post-transplant environment (Supplementary text 1). The patient achieved a favorable response to myeloma treatment and was in a stable plateau phase at +472 days.

The ASCT, when compared with the subsequent stage of durable virus control and normal ranges of lymphocyte subsets (data not shown), had diminished numbers of B, natural killer (NK), and NKT cells whereas T-cell numbers were overrepresented, consistent with the effects of CSFs prior to the harvest (Table 1) [22]. The kinetics of lymphocyte populations during virus rebound were also consistent with those of immune recovery post-transplantation including HIV-1–infected patients [22, 26]. This included increases in frequencies of NK subsets within weeks of transplant as well as a striking expansion of CD8+ T cells (Table 1). CD19+ B cells did not recover until after virus control had been regained (Table 1). Neutralizing antibody titers were modest (Supplementary Table 1) in comparison to titers commonly seen in chronic HIV-1 infection of viremic patients and individuals undergoing ART interruption [27, 28] and therefore are unlikely to have contributed to the control observed.

We used mathematical modeling [21] to determine whether the patient’s unique HIV-1 viral kinetics and cell death rates were consistent with established models of cytolytic immune cell viral control. A standard viral dynamic model, shown schematically in Figure 2A, was analyzed in which infected cells in the eclipse phase, $I_e$, transition to productive infection, $I_p$, and with both populations as well as long-lived infected cells, $M^*$, being potential targets of immune cell killing. In the model, cytolytic effectors, $E$, were stimulated by the presence of infected cells and grew with saturating kinetics. The model was represented as a system of differential equations and solved numerically (Supplementary material). The model was able to reproduce the VL changes observed in the patient (Figure 2B). Furthermore, by changing parameters, we were able to explore the effects of the different biological processes being modeled. We found that with parameters that resulted in a VL peak at about day 8, the effector cells that started at a low precursor frequency were still sufficient to expand rapidly near the peak VL and reproduce the viral load decline kinetics we observed (Figure 2B).

We determined whether HIV-1–specific CD8 T-cell responses were dominating the observed control. Although PBMCs prior to melphalan treatment were unavailable, we did have access to the ASCT taken 41 days before transplantation. We assumed that these cells were the baseline sample as they represented the major source of memory T cells at day 0. Mapping of HIV-1–specific T-cell responses identified epitopes in Gag and Pol detectable in the baseline and at subsequent time points (Figure 3A). Direct virus sequencing showed no amino acid changes in any of the Gag or Pol CD8 T-cell–restricted epitopes, indicating no virus escape from T cells during the study period (+472 days from transplantation; data not shown).

Focusing on the dominant HLA-B*81–restricted TL9 and L9 Gag-specific responses, we examined IFN-γ, tumor necrosis factor-alpha (TNF-α), and IL-2 production and expression of
CD107a+ lytic granules by intracellular cytokine flow cytometry before (∼41 days), during (+21 days), and after (+42 and +212 days) viral rebound. Very similar functional patterns were observed for both epitopes: 65% of baseline specific T cells exhibited >1 function and almost 20% exhibited triple IFN-γ, TNF-α, and CD107a expression following stimulation (Figure 3B). These proportions are consistent with functional profiles of HIV viremic controllers who exhibit broader CD8 T-cell functionality than viremic progressors [7]. During virus rebound (day 21), the proportion of single positive, largely IFN-γ or CD107a positive, cells increased in both the TL9- and LY9-specific populations by around 3-fold. By day 212, the functional phenotype of both cell populations was very similar to that observed at baseline. Analysis of the total measured functional T-cell response (at least 1 function) found that the TL9- and LY9-specific cells accounted for 2% of total memory CD8+ T cells in the baseline sample (Figure 3C), equating to approximately 26 million cells transferred in the ASCT (details presented in the “Methods” section). Upon virus reactivation, the TL9-specific functional T-cell response increased >4-fold (Figure 3C), and parallel HLA-B*81-TL9 tetramer staining showed that almost 16% of circulating memory CD8 T cells were specific following rebound (Figure 3D). TL9 reactive cells exhibited a CD45RO+CD27+ central memory phenotype (data not shown), and CD38 and PD1 staining showed that cells were highly activated around peak virus rebound. In contrast, CD57 levels, which are a hallmark of extensive cellular division, were stable during virus rebound (Figure 3E). These T-cell frequencies (Figure 3A), when combined with the high, absolute CD8 T-cell counts measured post-HIV reactivation (Figure 1), were consistent with the “effector” numbers that yielded virus control in our modeling analysis (Figure 2B).

We quantified the ability of the patient’s CD8 T cells to limit virus production following infection of autologous T cells with an HIV laboratory isolate. Fresh CD8 T cells isolated following control of HIV-1 viremia (days +326 and +354) reduced HIV-1 p24 derived from autologous CD4 T cells by 3 orders of magnitude by day 7 in culture (Figure 4A and 4B). We then estimated the in vitro t1/2 for virus inhibition. When autologous CD4 cells were infected in vitro, supernatant p24 increased at a rate of 0.75/day. In contrast, in the presence of autologous CD8 T cells at a 1:1 ratio, p24 decreased at a rate of 0.75/day, translating to a t1/2 of 0.93 days, which is similar to the rates of VL decline observed in vivo (Figure 1A).

**DISCUSSION**

Emerging data from laboratory studies relating to HIV-1 cure suggest that vaccination to stimulate the host immune response, particularly cytotoxic cells, may be critical to the clearing of reactivated HIV-1–infected cells following use of latency reversing agents (LRAs). However, evidence for this approach in humans is lacking, and parameters required for a vaccine are unknown because opportunities to study HIV-1 reactivation are extremely rare. We combined in vivo, in silico, and in vitro approaches to demonstrate for the first time that the human immune response
Human immunodeficiency virus type 1 (HIV-1)–specific CD8+ T-cell responses are highly functional, expanding strongly with control of HIV-1 reactivation. T-cell responses were initially mapped by interferon-gamma (IFN-γ) enzyme-linked immunospot at +336 days and were refined to optimal epitopes based on the patient’s human leukocyte antigen type. A, IFN-γ responses to mapped peptides were assayed in the baseline sample and peripheral blood mononuclear cells (PBMCs) at +42 days post-transplantation. Results represent mean ± standard deviation spot forming units/10^6 cells of triplicate measurements. B, Functionality of TL9 and LY9 CD8 memory T-cell responses before (−41 days, viral load [VL] <50), during (+21 days, VL measured at +19 and +23 days was 940 and 650 copies/mL, respectively), and after (+42 and +212 days, VL < 50) virus rebound. Colored arcs indicate cytokines. Shaded sectors show the proportion of each cytokine combination. C, Gag 180–188 (TL9) and Gag 78–86 (LY9) T-cell responses measured by intracellular cytokine flow cytometry prior to and during VL rebound. Percentage of CD8+ memory T cells expressing 1 or more of IFN-γ, tumor necrosis factor (TNF)-alpha, interleukin-2 (IL-2), and CD107a, as well as IFN-γ only, shown. D, Kinetics of B*81:01 Gag180–188 tetramer+ cells and VL during the study period. E, Changes in expression of activation markers CD57, PD-1, and CD38 by tetramer+ CD8 memory T cells during VL decline. Note: PBMCs prior to chemotherapy were unavailable; however, a sample from the leukapheresis at day −41 that was transplanted at day 0 was considered to be a baseline and representative of HIV-1–specific T-cell responses prior to chemotherapy.
is capable of controlling an iatrogenic large-scale HIV-1 reactivation, as might be induced by LRAs.

The data were derived from a HIV-1 seropositive EC who underwent myeloablation and ASCT as treatment for myeloma. The patient rapidly regained control of viral reactivation with kinetics comparable to those previously observed with ART. Our primary observation was the rapid rate of virus decline in the patient from day 13 to day 37 post-transplant. A biphasic decline was observed: the first slope, though derived from limited measurements, had a t_{1/2} of 0.71 (0.49–1.27) days and was equivalent to that observed in the most potent ART regimens. Notably, the higher estimate of 1.27 days was still classified as rapid in the absence of therapy and very similar to the estimated t_{1/2} of HIV-1 in post-peak virus decline in acute viremia [23]. The t_{1/2} in the second phase was 4.7 days, also comparable to observations in ART-treated patients.

In the absence of ART, what parameters produced these slopes in the patient? First, analysis of virus kinetics found that the virus upslope was more rapid than that observed in acute viremia [23]. This suggested that the rebounding virus in this EC was highly competent for replication in vivo, and therefore the virus itself could not explain the decline observed. A recent report also showed that virus isolates from ECs were fully replication-competent in vivo using a humanized mice model of HIV-1 infection [29]. Second, in the pre-ART era, HIV-1–infected noncontrollers undergoing similar myeloablation and transplantation procedures consistently exhibited high viremia post-transplant, indicating that the conditioning regimens do not, when used alone, constrain HIV-1 replication [30]. Further, analysis of pharmacokinetic data of the patient’s conditioning regimens indicated that they were unlikely to impact cell viability, which is consistent with the patient’s CD4 T-cell count, which remained >300 cells/mm³ as VL control was regained. In summary, the VL kinetics in the patient are not explained by poor virus replication nor limiting target cell availability.

During this rebound period, the patient’s HIV-1–specific CD8 T-cell response expanded strongly. This occurred in response to HIV-1 reactivation and was unlikely a by-product of homeostatic proliferation. In macaques, IL-15 treatment of durably suppressed SIV–infected monkeys similarly induced homeostatic proliferation of CD4 and CD8 effector T-cell subsets but did not increase SIV–specific T-cell responses [31]. T-cell mapping showed that in the patient, the immunodominant CD8 T-cell epitope corresponded to the dominant T-cell response observed in HLA-B*81:01 patients. This T-cell response has been detected in patients with acute HIV-1 infection, including those who subsequently achieved elite control. The target epitope is highly conserved at the population level, and subsequent escape is associated with significant loss of replicative fitness [20, 32]. We followed the kinetics of the dominant T-cell responses and found strong expansion in response to virus rebound, though without evidence that cells were terminally expanded. These cell populations rapidly declined following reacquisition of virus control. No virus escape through mutation of T-cell epitopes was observed during the period of study, consistent with T cells exerting an ongoing immune pressure. Analysis of other CD8 T-cell functions during the rebound period found that HIV-1–specific cells became highly activated and, interestingly, appeared to exhibit reduced oligofunctionality relative to HIV-1–specific cells analyzed at baseline. Activation levels rapidly subsided when virus control was regained, with broader functionality in terms of cytokine and lytic marker production again observed.

Last, strong in vitro suppression of HIV was observed at a subsequent time point following virus control (when HIV-1–specific CD8 T-cell frequencies were much lower). Importantly, the frequencies of the patient’s HIV-1–specific T-cell responses,
when combined with the high, absolute CD8 T-cell counts measured post-HIV reactivation, were consistent with the "effector" numbers in modeling that produced VL kinetics very similar to that observed in our patient. Together, these data suggest that the patient’s HIV-1–specific CD8 T-cell response following reactivation directly contributed to the virus control observed. This hypothesis is further supported by recent studies of viremic controller macaques in which virus rebound following CD8 depletion by antibodies and regain of virus control as CD8 T-cells returned were observed [14, 15]. Additional support is garnered from the transplantation biology setting where cytomegalovirus (CMV) reactivation is often observed post-transplantation, with the level of CMV-reactive CD8 T cells correlating with control of CMV viremia [33].

However, as a single patient study, our observations are associative. We cannot quantify the precise in vivo contribution of CD8 T-cells to the control observed and do not exclude a role for other subsets, particularly NK cells, in this patient, contributing either directly to anti-HIV-1 cytotoxicity or indirectly by conferring a clinical benefit against the patient’s myeloma [34]. The T-cell responses induced in this patient were typical of those induced in other ECs, suggesting that vaccination regimens that induce broadly functional CD8 T-cell responses, with good replicative potential and targeting conserved regions of HIV-1, might be more effective at recognizing and clearing reactivated HIV-infected cells. However, challenges to this approach still remain, for example, the requirement for immune-boosting strategies that target conserved, unmutated epitopes following the recent finding that HIV-1 proviruses in latently infected cells from chronically infected patients almost always contain cytoxic T lymphocyte escape mutations [35].

Supplementary Data

Supplementary materials are available at Clinical Infectious Diseases online (http://cid.oxfordjournals.org). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyrighted. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Notes

Acknowledgments. We thank the study participant as well as Samantha Darby, Jude Dorman, Stuart Kirk, Jonathan Lambert, James Davies, Stephane Hue, Camille Lange, Mala Maini, Dimitra Peppa, John Frater, and Lyle Murray.


Ethics statement. Ethical approval for this research was given by the National Research Ethics Service Committee London–Harrow. The study participant provided written informed consent.

Financial support. This work was supported by the Wellcome Trust Fellowship to R. K. G. (WT093722MA) and the European Community’s Seventh Framework Programme (FP7/2007–2013) under the project Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN; 223131). We also acknowledge support from the National Institutes for Health Research University College London Hospitals Biomedical Research Centre and National Institutes of Health for A. S. P. (AI028433 and OD011095). N. G. was supported by the McMichael Trust Fund at Oxford University and a Creative and Novel Ideas in HIV research award (AI022776); N. M. G. S. and A. J. M. were supported by the Medical Research Council.

Potential conflicts of interest. S. G. E. has received funding from Boehringer to attend conferences and received lecture fees from Gilead, and Janssen. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References


